Loading…
Thursday, October 3 • 2:00pm - 2:10pm
Lightning Session- Rapid Automated Computation, Coupling, Cleavage, Chromatography Execution (RAC4E) Platform Driving Drug Discovery

Sign up or log in to save this to your schedule and see who's attending!

Rapid Automated Computation, Coupling, Cleavage, Chromatography Execution (RAC4E) Platform Driving Drug Discovery
Synthetic peptide therapeutics have played a notable role in medical advances over the past two decades with a more recent focus on diagnostics and personalized therapeutics, however, the field has struggled with a slow pace of discovery, optimization, and manufacturing due to limitations in the manufacturing processes – coupling, cleavage, and chromatography. Advances in laboratory automation have helped improve the productivity of expert scientists; however, these technologies have not been able to meet the demand for custom peptide sequences to enable rapid, cost-effective drug discovery, especially when compared to DNA synthesis. Inefficient synthesis techniques often take weeks, if not months, to produce the target molecule, becoming a major bottleneck in the drug discovery pipeline. Given that peptides are assembled from one reaction and a discrete number of building blocks, machine learning (ML) has the ability to drastically increase the speed of manufacturing by enabling sequence-specific optimization, significantly reducing the overall drug discovery time.

Mytide’s Rapid Automated Computation, Coupling, Cleavage, and Chromatography Execution (RAC4E) platform takes a holistic approach to peptide manufacturing starting with the use of ML models to inform sequence-specific strategies while closing the loop with data collection at every process step, which feeds back into future synthesis plans. Our solid-phase slug flow (SPSF) technology offers the opportunity to combine real-time process analytics with ML models to provide a tailored coupling process for each and every individual sequence produced. Integrating optimization strategies into RAC4E serves as a foundation for efficient library development, leading the way for direct synthesis to bioassays driving innovation with our collaborators, partners and internal drug discovery pipelines.

Authors: Dale Thomas, PhD; Justin Lummiss, PhD; Kevin Shi, PhD; Chase Olle, MEngM

Speakers
avatar for Dale Thomas, PhD

Dale Thomas, PhD

Co-Founder, Mytide Therapeutics
Dale Thomas III, Ph.D. (Co-Founder): he spanned both Mechanical Engineering and Chemical Engineering at MIT. He also completed his MEngM at MIT and BS at Maine Maritime Academy. In his research, he developed an array of flow chemistry platforms for the advanced synthesis of pharmaceuticals... Read More →

Chairs
avatar for Mike Berke, MS

Mike Berke, MS

Director of Research and Automation Technologies, Amgen
Mike is the Director of the Research & Automation Technologies (R&AT) group at Amgen, where he has been for the last 16 years. The R&AT group focuses on developing novel devices and software tools to improve research processes.


Thursday October 3, 2019 2:00pm - 2:10pm
Theater Ballroom (5th Fl) - Courtyard Boston Downtown 275 Tremont Street, Boston, MA 02116